Related Experiment Videos

Complement receptors (C3b, C4b/C3d) unbalance on CLL lymphocytes

Bollettino Dell'Istituto Sieroterapico Milanese
|July 31, 1976
PubMed

Insights

Chronic Lymphatic Leukemia (CLL) patients show increased C3d complement receptor (CRL) levels on lymphocytes. Treatment appears to reduce all CRL types non-selectively in CLL patients.

Area of Science:

  • Immunology
  • Hematology
  • Complement System

Background:

  • Lymphocytes play a crucial role in immune responses.
  • Complement receptors (CRLs) on lymphocytes are involved in immune regulation.
  • Chronic Lymphatic Leukemia (CLL) is a hematological malignancy characterized by abnormal lymphocyte proliferation.

Purpose of the Study:

  • To investigate complement receptor (CRL) expression on lymphocytes in healthy donors and CLL patients.
  • To analyze the effect of treatment on CRL expression in CLL.
  • To hypothesize the immunophenotype of proliferating lymphocytes in CLL.

Main Methods:

  • Analysis of lymphocytes from human peripheral blood using immunoadherence assays.
  • Quantification of lymphocytes bearing C3b, C4b, and C3d complement receptors (CRLs).
  • Comparison of CRL expression between healthy controls, CLL patients, and CLL patients undergoing treatment.

Main Results:

  • A significant increase in C3dCRL-bearing lymphocytes was observed in CLL patients compared to controls.
  • Lymphocytes with immunoadherence receptors were also slightly augmented in CLL patients.
  • CRL populations in CLL patients under treatment mirrored the profile of untreated CLL, suggesting non-selective reduction.

Conclusions:

  • CLL lymphocytes exhibit altered complement receptor expression, particularly an elevation of C3dCRL.
  • Current treatments may not selectively target specific CRL types on lymphocytes in CLL.
  • The proliferating lymphocyte population in CLL is hypothesized to be predominantly sIg+, C3d+/C3b-, C4b-, with a subset also being C3d+/C3b+, C4b+.

Related Concept Videos